作为胆固醇的替代品,迪奥斯基宁通过影响CYP7A1和NPC1L1相关途径来缓解NAFLD
Mengyao Yan1, Yixin Zhao1, Shuli Man1
1State Key Laboratory of Food Nutrition and Safety, Key Laboratory of Industrial Microbiology, Ministry of Education, Tianjin Key Laboratory of Industry Microbiology, National and Local United Engineering Lab of Metabolic Control Fermentation Technology, China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science & Technology, Tianjin, 300457, China.
迪奥斯基宁通过调节胆固醇代谢,有效治疗非酒精性脂肪性肝病 (NAFLD). 这项研究表明,迪奥斯基宁抑制关键酶,为NAFLD提供了潜在的新疗法.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 非酒精性脂肪性肝病 (NAFLD) 是终末期肝病的日益严重的原因,目前还没有批准的治疗方法.
- 胆固醇代谢失调是NAFLD进展的关键因素.
- 胆固醇模拟物迪奥斯基宁可能为NAFLD提供治疗潜力.
研究的目的:
- 为了研究 diosgenin 的抗NAFLD 作用.
- 阐明迪奥斯基宁调节NAFLD胆固醇代谢的机制.
主要方法:
- 高脂肪/果糖饮食诱导的NAFLD小鼠模型.
- 转录组测序,LC/MS,分子对接和分子动力学模拟.
- Luci光记者基因测定用于评估酶活性.
主要成果:
- 迪奥斯基宁改善了肝功能障碍和NAFLD的特征 (脂质积累,炎症,纤维化).
- 迪奥斯基宁降低了CYP7A1的表达和胆酸合成 (CDCA,CA,TCA).
- 迪奥斯基宁通过降低NPC1L1表达和直接抑制CYP7A1活性来抑制胆固醇运输.
结论:
- 狄奥斯基宁作为NAFLD中胆固醇代谢的特定调节剂.
- 迪奥斯基宁在NAFLD治疗中显示出显著的治疗潜力.
- 这些发现为新的NAFLD临床治疗策略铺平了道路.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Cell Specific Gene Expression
Cholesterol: Significance and Regulation
Considering cholesterol and...
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:


